Optical detection of the structural properties of tumor tissue generated by xenografting of drug-sensitive and drug-resistant cancer cells using partial wave spectroscopy (PWS).
暂无分享,去创建一个
Meena Jaggi | Murali M Yallapu | Prakash Adhikari | Prashanth K B Nagesh | Fatemah Alharthi | Subhash C Chauhan | Prabhakar Pradhan | M. Jaggi | P. Pradhan | P. K. Nagesh | S. Chauhan | P. Adhikari | Fatemah Alharthi | M. Yallapu
[1] P. Pradhan,et al. Light localization properties of weakly disordered optical media using confocal microscopy: application to cancer detection. , 2017, Optics express.
[2] F. Liu,et al. New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer , 2015, Oncology reports.
[3] Aris Persidis,et al. Cancer multidrug resistance , 1999, Nature Biotechnology.
[4] A. Yagoda,et al. Cytotoxic chemotherapy for advanced hormone‐resistant prostate cancer , 1993, Cancer.
[5] J. Nickerson,et al. Nuclear dreams: The malignant alteration of nuclear architecture , 1998, Journal of cellular biochemistry.
[6] A. Aref,et al. Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance , 2019, Molecular Cancer.
[7] J. Machiels,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial , 2010, The Lancet.
[8] Peter J Houghton,et al. Establishment of human tumor xenografts in immunodeficient mice , 2007, Nature Protocols.
[9] Allen Taflove,et al. Quantification of nanoscale density fluctuations by electron microscopy: probing cellular alterations in early carcinogenesis , 2011, Physical biology.
[10] Allen Taflove,et al. Optical methodology for detecting histologically unapparent nanoscale consequences of genetic alterations in biological cells , 2008, Proceedings of the National Academy of Sciences.
[11] Vadim Backman,et al. Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. , 2009, Cancer research.
[12] Daniele Zink,et al. Nuclear structure in cancer cells , 2004, Nature Reviews Cancer.
[13] J. D. de Bono,et al. Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise. , 2018, Cold Spring Harbor perspectives in medicine.
[14] M. Jaggi,et al. Quantification of photonic localization properties of targeted nuclear mass density variations: Application in cancer‐stage detection , 2018, Journal of biophotonics.
[15] Subhas C. Kundu,et al. Sequential release of drugs from hollow manganese ferrite nanocarriers for breast cancer therapy. , 2015, Journal of materials chemistry. B.
[16] Allen Taflove,et al. Quantification of nanoscale density fluctuations using electron microscopy: Light-localization properties of biological cells. , 2010, Applied physics letters.
[17] Vadim Backman,et al. Association between rectal optical signatures and colonic neoplasia: potential applications for screening. , 2009, Cancer research.
[18] B. Konety,et al. Nuclear structural proteins as biomarkers of cancer , 1999, Journal of cellular biochemistry.
[19] T. Yang,et al. Insights into Chemoresistance of Prostate Cancer , 2015, International journal of biological sciences.
[20] V. Backman,et al. Partial-wave microscopic spectroscopy detects subwavelength refractive index fluctuations: an application to cancer diagnosis. , 2009, Optics letters.
[21] Vadim Backman,et al. Role of cytoskeleton in controlling the disorder strength of cellular nanoscale architecture. , 2010, Biophysical journal.
[22] Murali M. Yallapu,et al. Optical study of chemotherapy efficiency in cancer treatment via intracellular structural disorder analysis using partial wave spectroscopy , 2017, Journal of biophotonics.
[23] M. Michael,et al. Tumoral drug metabolism: overview and its implications for cancer therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Sarah A Heerboth,et al. Drug Resistance in Cancer: An Overview , 2014, Cancers.
[25] D. Osoba,et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Shikhar Uttam,et al. Nanoscale nuclear architecture for cancer diagnosis beyond pathology via spatial-domain low-coherence quantitative phase microscopy. , 2010, Journal of biomedical optics.
[27] W. V. van Weerden,et al. Use of nude mouse xenograft models in prostate cancer research , 2000, The Prostate.
[28] Jean-Pierre Gillet,et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance , 2011, Proceedings of the National Academy of Sciences.